| β-Adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects JD Blumenfeld, JE Sealey, SJ Mann, A Bragat, R Marion, MS Pecker, ... American journal of hypertension 12 (5), 451-459, 1999 | 194 | 1999 |
| Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 … DP Germain, R Giugliani, DA Hughes, A Mehta, K Nicholls, L Barisoni, ... Orphanet journal of rare diseases 7, 1-11, 2012 | 165 | 2012 |
| Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 … DP Germain, R Giugliani, DA Hughes, A Mehta, K Nicholls, L Barisoni, ... Orphanet journal of rare diseases 7, 1-11, 2012 | 165 | 2012 |
| A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects R Giugliani, S Waldek, DP Germain, K Nicholls, DG Bichet, JK Simosky, ... Molecular Genetics and Metabolism 109 (1), 86-92, 2013 | 126 | 2013 |
| Apixaban, a direct factor Xa lnhibitor: Single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation C Frost, Z Yu, S Nepal, A Bragat, K Moore, A Shenker, Y Barret, F LaCreta JOURNAL OF CLINICAL PHARMACOLOGY 48 (9), 1132-1132, 2008 | 59 | 2008 |
| Pharmacokinetics and safety of migalastat HCl and effects on agalsidase activity in healthy volunteers FK Johnson, PN Mudd Jr, A Bragat, M Adera, P Boudes Clinical Pharmacology in Drug Development 2 (2), 120-132, 2013 | 41 | 2013 |
| Novel quantitative method to evaluate globotriaosylceramide inclusions in renal peritubular capillaries by virtual microscopy in patients with fabry disease L Barisoni, JC Jennette, R Colvin, S Sitaraman, A Bragat, J Castelli, ... Archives of pathology & laboratory medicine 136 (7), 816-824, 2012 | 26 | 2012 |
| Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. AC Bragat, J Blumenfeld, JE Sealey Journal of hypertension 15 (5), 459-465, 1997 | 24 | 1997 |
| Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects C Frost, A Shenker, S Jhee, Z Yu, J Wang, A Bragat, J Pursley, F LaCreta Clinical Pharmacology: Advances and Applications, 153-163, 2018 | 10 | 2018 |
| Single dose apixaban pharmacokinetics and pharmacodynamics in healthy male Japanese and Caucasian subjects Z Yu, S Nepal, A Bragat Can J Clin Pharmacol 15, e724, 2008 | 9 | 2008 |
| Migalastat reduces plasma globotriaosylsphingosine (lyso-Gb3) in Fabry patients: results from the FACETS phase 3 study ER Benjamin, R Hamler, N Brignol, R Boyd, J Yu, A Bragat, J Kirk, ... J Inherit Metab Dis 37 (Suppl 1), S161, 2014 | 6 | 2014 |
| Preliminary long-term safety, tolerability, and assessments of renal function of adult Fabry patients receiving treatment with AT1001 (migalastat hydrochloride), a … D Hughes, M Adera, J Castelli, A Bragat, DL Marsden, PB Boudes J Inherit Metab Dis 33, S148-S148, 2010 | 6 | 2010 |
| Phase 3 study of migalastat HCl for Fabry disease: Stage 1 results K Nicholls, DP Germain, C Feliciani, S Shankar, F Ezgu, SG Janmohamed, ... Molecular Genetics and Metabolism 2 (108), S70, 2013 | 5 | 2013 |
| A040: Omapatrilat increases plasma concentration of adrenomedullin in salt-sensitive hypertensives O Vesterqvist, VM Campese, W Liao, JA Manning, AC Bragat, CL Delaney, ... American Journal of Hypertension 13 (S2), 125A, 2000 | 5 | 2000 |
| Pharmacokinetics and muscle distribution of at2220, a pharmacological chaperone of acid-glucosidase, in healthy volunteers M Adera, P Boudes, A Bragat, S Sitaraman, R Lazauskas, K Valenzano, ... Molecular Genetics and Metabolism 102 (2), S4, 2011 | 4 | 2011 |
| Westgard QC A Six Sigma Method Decision Chart spreadsheet A Bragat | 2 | |
| Preparing a Successful Scientific Abstract for Professional Meetings in the Data Sciences RF Ittenbach Journal of the Society for Clinical Data Management, 2020 | 1 | 2020 |
| Novel Quantitative Virtual Microscopy-Based method to evaluate GL-3 inclusions in renal peritubular capillaries in patients with Fabry disease L Barisoni, CJ Jennette, RB Colvin, P Boudes, S Sitaraman, J Castelli, ... HISTOPATHOLOGY 57, 239-239, 2010 | 1 | 2010 |
| EFFECT OF OMAPATRILAT AND LISINOPRIL ON PLASMA CONCENTRATIONS OF ADRENOMEDULLIN IN PATIENTS WITH SALT-SENSITIVE HYPERTENSION: P3. 42 O Vesterqvist, W Liao, JA Manning, AC Bragat, CL Delaney, VM Campese Journal of Hypertension 18, S162, 2000 | 1 | 2000 |
| EFFECTS OF B-BLOCKADE ON BLOOD-PRESSURE (BP), PRORENIN (PRO), RENIN (PRA) AND ANGIOTENSIN-II (ANGII) AND ITS INTERACTION WITH CAPTOPRIL (CAP) IN NORMOTENSIVES (NT) AND … JD Blumenfeld, JE Sealey, AC Bragat, RM MARION, JH LARAGH JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 6 (3), 638-638, 1995 | 1 | 1995 |
Roberto GiuglianiHead of Rare Diseases DASA, Founder CASA DOS RAROS, Med Genet Serv HCPA, Dep Genetics & PPGBM UFRGSDirección de correo verificada de hcpa.edu.br
